IRLAB Therapeutics AB (OSTO:IRLAB A) Operating Cash Flow per Share : kr-0.44 (TTM As of Mar. 2025)

View and export this data going back to 2017. Start your Free Trial

What is IRLAB Therapeutics AB Operating Cash Flow per Share?

IRLAB Therapeutics AB's operating cash flow per share for the three months ended in Mar. 2025 was kr0.12. IRLAB Therapeutics AB's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2025 was kr-0.44.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for IRLAB Therapeutics AB's Operating Cash Flow per Share or its related term are showing as below:

During the past 12 years, IRLAB Therapeutics AB's highest 3-Year average Operating Cash Flow per Share Growth Rate was -3.60% per year. The lowest was -54.90% per year. And the median was -14.75% per year.

OSTO:IRLAB A's 3-Year OCF Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 9.5
* Ranked among companies with meaningful 3-Year OCF Growth Rate only.

IRLAB Therapeutics AB Operating Cash Flow per Share Historical Data

The historical data trend for IRLAB Therapeutics AB's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IRLAB Therapeutics AB Operating Cash Flow per Share Chart

IRLAB Therapeutics AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Operating Cash Flow per Share

Get a 7-Day Free Trial

-1.87

2.49

-2.75

-3.18

-1.27

IRLAB Therapeutics AB Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Operating Cash Flow per Share	Get a 7-Day Free Trial															-0.74	-	-0.13	-0.44	0.12

Competitive Comparison of IRLAB Therapeutics AB's Operating Cash Flow per Share

For the Biotechnology subindustry, IRLAB Therapeutics AB's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IRLAB Therapeutics AB's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IRLAB Therapeutics AB's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where IRLAB Therapeutics AB's Price-to-Operating-Cash-Flow falls into.

Save Embed

;

Save Embed

;

IRLAB Therapeutics AB Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

IRLAB Therapeutics AB's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2024 is calculated as

Operating Cash Flow per Share (A: Dec. 2024 )	=	Cash Flow from Operations (A: Dec. 2024 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2024 )
	=	-65.59	/	51.868
	=	-1.26

IRLAB Therapeutics AB's Operating Cash Flow per Share for the quarter that ended in Dec. 2024 is calculated as

Operating Cash Flow per Share (Q: Mar. 2025 )	=	Cash Flow from Operations (Q: Mar. 2025 )	/	Shares Outstanding (Diluted Average) (Q: Mar. 2025 )
	=	6.332	/	51.868
	=	0.12

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.44

IRLAB Therapeutics AB Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of IRLAB Therapeutics AB's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

IRLAB Therapeutics AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IRLAB Therapeutics AB (OSTO:IRLAB A) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

Arvid Wallgren Backe 20, Goteborg, SWE, 413 46

Website

https://www.irlab.se

IRLAB Therapeutics AB is a drug discovery and development company providing novel treatments for disorders of the brain. The company focuses on innovative treatments and quality of life for patients with neurological and psychiatric illnesses. It is engaged in programs targeting core dysfunctions in Parkinson's disease and dementias. In addition, it is also involved in the clinical development of novel compounds which aims at offering improved clinical benefit for patients with Parkinson's disease. The company's current clinical candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which have successfully gone through Phase I safety and Phase IIa efficacy proof-of-concept studies, are now in Phase IIb trials.

IRLAB Therapeutics AB Headlines

No Headlines